WilmerHale Reps Editas Medicine in $94.4 Million IPO

WilmerHale Reps Editas Medicine in $94.4 Million IPO

Firm News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Lawyers with deep and broad experience counseling clients in every industry on the design, implementation, and interpretation of executive compensation arrangements and on general compensation and benefits issues.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented Massachusetts-based gene editing company Editas Medicine in its $94.4 million initial public offering, which occurred on February 2, 2016. The IPO was the first in the US in 2016.

The WilmerHale team on the transaction was led by Partners Steven D. Singer and Rosemary G. Reilly and included Counsel Jeffries Oliver-Li, and Associates Britt Eichner and Brett Bromann (corporate); as well as Partner Kim Wethly and Counsel Ciara Baker (tax). 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel